July 18, 2016
(MIT Technology Review) – The goal of precision medicine is to provide drugs and therapies that are uniquely suited to individual patients based on their genetics and other distinguishing health information. To a small degree, that already is happening. Dozens of targeted drugs have gotten approval from the U.S. Food and Drug Administration in recent years, and there are particularly successful examples in oncology. But despite the early successes, we are many years from realizing a “new era of medicine” the president described in his 2015 State of the Union address—if we can realize it at all.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.